

GLYCOPYRROLATE- glycopyrrolate tablet **Quinn Pharmaceuticals**


GLYCOPYRROLATE TABLETS USP

Description

Glycopyrrolate tablets contain the synthetic anticholinergic, glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1, 1-dimethylpyrrolidinium bromide.

Each glycopyrrolate tablet USP, intended for oral administration, contains glycopyrrolate equivalent to 1 mg or 2 mg. In addition, it also contains the following inactive ingredients: lactose monohydrate, dibasic calcium phosphate anhydrous, povidone, sodium starch glycolate and magnesium stearate.

The structural formula of glycopyrrolate is represented below:



Molecular Formula: C₁₉H₂₈BrNO₃

Molecular Weight: 398.33

Each tablet contains 1 mg or 2 mg of Glycopyrrolate, USP.

Inactive Ingredients: Microcrystalline cellulose, lactose monohydrate, pregelatinized starch, magnesium stearate

CLINICAL PHARMACOLOGY

Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sino-atrial node, the atrioventricular node, exocrine glands, and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.

Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the

anticholinesterases.

The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are non-polar tertiary amines which penetrate lipid barriers easily.

INDICATIONS AND USAGE

For use as adjunctive therapy in the treatment of peptic ulcer.

CONTRAINDICATIONS

Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Glycopyrrolate Tablets, USP are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

WARNINGS

In the presence of a high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with the use of Glycopyrrolate.

Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.

Glycopyrrolate may produce drowsiness or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking this drug.

Theoretically, with overdosage, a curare-like action may occur, i.e., neuro-muscular blockade leading to muscular weakness and possible paralysis.

Pregnancy

The safety of this drug during pregnancy has not been established. The use of any drug during pregnancy requires that the potential benefits of the drug be weighed against possible hazards to mother and child. Reproduction studies in rats revealed no teratogenic effects from glycopyrrolate; however, the potent anticholinergic action of this agent resulted in diminished rates of conception and of survival at weaning, in a dose-related manner. Other studies in dogs suggest that this may be due to diminished seminal secretion which is evident at high doses of glycopyrrolate. Information on possible adverse effects in the pregnant female is limited to uncontrolled data derived from marketing experience. Such experience has revealed no reports of teratogenic or other fetus-damaging potential. No controlled studies to establish the safety of the drug in pregnancy have been performed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

Pediatric Use

Since there is no adequate experience in pediatric patients who have received this drug, safety and efficacy in pediatric patients have not been established.

PRECAUTIONS

Use glycopyrrolate with caution in the elderly and in all patients with:

- Autonomic neuropathy.
- Hepatic or renal disease.
- Ulcerative colitis-large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason may precipitate or aggravate "toxic megacolon," a serious complication of the disease.
- Hyperthyroidism, coronary heart disease, congestive heart failure, cardiac tachyarrhythmias, tachycardia, hypertension and prostatic hypertrophy.
- Hiatal hernia associated with reflux esophagitis, since anticholinergic drugs may aggravate this condition.

ADVERSE REACTIONS

Anticholinergics produce certain effects, most of which are extensions of their fundamental pharmacological actions. Adverse reactions to anticholinergics in general may include xerostomia; decreased sweating; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; dilatation of the pupil; cycloplegia; increased ocular tension; loss of taste; headaches; nervousness; mental confusion; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; constipation; bloated feeling; impotence; suppression of lactation; severe allergic reaction or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.

OVERDOSAGE

The symptoms of overdosage of glycopyrrolate are peripheral in nature rather than central.

1. To guard against further absorption of the drug-use gastric lavage, cathartics and/or enemas.
2. To combat peripheral anticholinergic effects (residual mydriasis, dry mouth, etc.)-utilize a quaternary ammonium anticholinesterase, such as neostigmine methylsulfate.
3. To combat hypotension-use pressor amines (norepinephrine, metaraminol) i.v.; and supportive care.
4. To combat respiratory depression-administer oxygen; utilize a respiratory stimulant such as Dopram[®] i.v.; artificial respiration.

DOSAGE AND ADMINISTRATION

The dosage of Glycopyrrolate Tablets, USP 1 mg and 2 mg should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse reactions. The presently recommended maximum daily dosage of glycopyrrolate is 8 mg.

Glycopyrrolate Tablets, USP 1 mg

The recommended initial dosage of Glycopyrrolate Tablets, USP 1 mg for adults is one tablet three times daily (in the morning, early afternoon, and at bedtime). Some patients may require two tablets at bedtime to assure overnight control of symptoms. For maintenance, a dosage of one tablet twice a day is frequently adequate.

Glycopyrrolate Tablets, USP 2 mg

The recommended dosage of Glycopyrrolate Tablets, USP 2 mg for adults is one tablet two or three times daily at equally spaced intervals.

Glycopyrrolate tablets are not recommended for use in pediatric patients under the age of 12 years.

DRUG INTERACTIONS

There are no known drug interactions.

HOW SUPPLIED

Glycopyrrolate Tablets, USP 1 mg are uncoated, round, flat face white tablets with beveled edge and debossed with "0475" on one side and bisected on the other.

Glycopyrrolate Tablets, USP 1 mg in bottles of 100

(NDC 69076-475-01).

Glycopyrrolate Tablets, USP 2 mg are uncoated, round, flat face white tablets with beveled edges and debossed with "0476" on one side and bisected on the other.

Glycopyrrolate Tablets, USP 2 mg in bottles of 100

(NDC 69076-476-01).

Store at controlled room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C-30°C (59°F-86°F) [See USP Controlled Room Temperature]. Keep out of reach of children.

Dispense in tight container.

Rx only

Manufactured by:

Contract Pharmacal Corp.

165 Oser Avenue

Hauppauge, NY 11788

Distributed by:
Quinn Pharmaceuticals
954-755-0502
www.quinnrx.com

Made in USA

Rev: 03/2021 (4)

R50242

Quinn Pharmaceuticals

NDC 69076-475-01

Rx only

Glycopyrrolate Tablets, USP

1 mg

WHITE DYE-FREE

100 Tablets

Quinn Pharmaceuticals

NDC 69076-475-01

Rx only

Glycopyrrolate Tablets, USP

1 mg

WHITE DYE-FREE

100 Tablets

Each tablet contains: Glycopyrrolate, USP 1 mg.

USUAL DOSAGE: One or two tablets three times a day. See accompanying information.

STORAGE: Store at controlled room temperature, 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep out of the reach of children.

PHARMACIST: Dispense in a tight container.

Distributed by:
Quinn Pharmaceuticals
Boca Raton, FL
954-755-0502
www.quinnrx.com
Made in U.S.A.

Manufactured by:
Contract Pharnacal Corp.
165 Oser Avenue
Hauppauge, NY 11788

Rev. 03/2021 (16)
R50241

69076 47501 4

Quinn Pharmaceuticals

NDC 69076-476-01

Rx only

Glycopyrrolate Tablets, USP

2 mg

WHITE DYE-FREE

100 Tablets



NDC 69076-476-01

Rx only

Glycopyrrolate Tablets, USP

2 mg



WHITE DYE-FREE **100 Tablets**

Each tablet contains: Glycopyrrolate, USP 2 mg.
USUAL DOSAGE: One tablet two or three times a day. See accompanying information.
STORAGE: Store at controlled room temperature, 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep out of the reach of children.
PHARMACIST: Dispense in a tight container.

Distributed by: Quinn Pharmaceuticals, Boca Raton, FL 954-755-0502, www.quinnrx.com, Made in U.S.A.
 Manufactured by: Contract Pharmacal Corp., 165 Oser Avenue, Hauppauge, NY 11788



Rev. 03/2021 (16)
R50243

GLYCOPYRROLATE

glycopyrrolate tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:69076-475
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
GLYCOPYRROLATE (UNII: V92S09WP2I) (GLYCOPYRRONIUM - UNII:A14FB57V1D)	GLYCOPYRROLATE	1 mg

Inactive Ingredients

Ingredient Name	Strength
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)	
STARCH, PREGELATINIZED CORN (UNII: O8232NY3SJ)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	

Product Characteristics

Color	white (White)	Score	2 pieces
Shape	ROUND (round)	Size	8mm
Flavor		Imprint Code	0475
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:69076-475-01	100 in 1 BOTTLE; Type 0: Not a Combination Product	05/01/2021	

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA091182	05/01/2021	

GLYCOPYRROLATE				
glycopyrrolate tablet				
Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:69076-476	
Route of Administration	ORAL			
Active Ingredient/Active Moiety				
	Ingredient Name	Basis of Strength	Strength	
	GLYCOPYRROLATE (UNII: V92S09WP2I) (GLYCOPYRRONIUM - UNII:A14FB57V1D)	GLYCOPYRROLATE	2 mg	
Inactive Ingredients				
	Ingredient Name	Strength		
	CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)			
	LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)			
	STARCH, PREGELATINIZED CORN (UNII: O8232NY3SJ)			
	MAGNESIUM STEARATE (UNII: 70097M6I30)			
Product Characteristics				
Color	white (White)	Score	2 pieces	
Shape	ROUND (round)	Size	10mm	
Flavor		Imprint Code	0476	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:69076-476-01	100 in 1 BOTTLE; Type 0: Not a Combination Product	05/01/2021	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA091182	05/01/2021	

Labeler - Quinn Pharmaceuticals (084014259)

Registrant - Stason Pharmaceuticals, Inc. (807437553)

Revised: 4/2021

Quinn Pharmaceuticals